Hepion pharmaceuticals’ crv431 prevents cirrhosis in experimental model of severe liver disease

Hepion pharmaceuticals, inc. announced that crv431, an anti-fibrotic agent, prevented the development of liver cirrhosis in a highly aggressive, preclinical model of liver disease. in this study, conducted by physiogenex, s.a.s. (france), rats were administered the hepatotoxic compound, thioacetamide, for nine weeks to induce liver injury and fibrosis, in combination with either crv431 or vehicle control for the entire study period. blinded, histopathological analysis of the livers was conducted at the end of the study period. in the vehicle control group, 50% (5 out of 10) of the animals developed cirrhosis, a severe form of liver disease that includes maximum levels of fibrotic scarring (f4 fibrosis; kleiner scoring system). in contrast, none of the 10 crv431-treated rats developed cirrhosis. quantification of sirius red histological staining, another measure of fibrotic scarring, similarly revealed a mean reduction in the crv431 treatment group of 49% compared to the vehicle control group, which was statistically significant (p = 0.008). these results suggest that the anti-fibrotic activity of crv431 was primarily responsible for attenuating the progression to cirrhosis over the duration of the study.
HEPA Ratings Summary
HEPA Quant Ranking